文献速递免疫规划妇幼与学校卫生

2024-25年美国孕妇与婴儿呼吸道疾病免疫接种覆盖情况

Maternal and infant immunizations for respiratory diseases, United States, may 2025.
PubMed 文献 · Vaccine · 2026-06-12

基于2025年3-5月网络调查的2738名孕妇数据,评估2024-25呼吸道疾病季节流感、Tdap、COVID-19和RSV疫苗接种率。结果显示孕妇流感疫苗覆盖51.0%、Tdap 52.6%、COVID-19 32.3%、RSV疫苗49.3%,婴儿nirsevimab覆盖62.2%,70.4%婴儿通过母体疫苗或nirsevimab获得保护。提供者推荐与接种率正相关,疫苗犹豫与接种率负相关。

要点

  • 孕妇流感疫苗覆盖51.0%,Tdap 52.6%,COVID-19 32.3%,RSV疫苗49.3%。
  • 提供者推荐者接种率显著更高:流感65.6% vs 12.2%,Tdap 69.5% vs 2.9%,COVID-19 56.4% vs 4.4%。
  • 70.4%婴儿通过母体RSV疫苗、nirsevimab或两者获得保护。

核心结论

  • 提供者推荐和疫苗犹豫与孕妇疫苗 uptake 相关,支持提供者与孕妇之间信息性疫苗对话可能提高保护比例。

研究设计与样本

  • 分析2025年3月26日至5月8日进行的互联网面板调查数据,纳入2738名当前或近期孕妇,各疫苗分析限于符合特定产品条件的子样本。

主要发现

  • 符合条件参与者中,51.0%报告孕前或孕期接种流感疫苗,52.6%孕期接种Tdap,32.3%孕前或孕期接种2024-25 COVID-19疫苗,49.3%孕期接种RSV疫苗。
  • 1416名符合条件婴儿的母亲中,62.2%报告婴儿接受nirsevimab;总体70.4%婴儿通过母体RSV疫苗、nirsevimab或两者获得保护。
  • 有提供者推荐者接种率高于无推荐者:流感65.6% vs. 12.2%,Tdap 69.5% vs. 2.9%,COVID-19 56.4% vs. 4.4%。
  • Tdap提供者推荐率在非西班牙裔黑人(66.4%)和西班牙裔女性(60.1%)中低于非西班牙裔白人女性(83.2%)。
  • 报告对特定疫苗非常/有些犹豫的女性比不犹豫女性更不可能接种该疫苗。

临床怎么用

  • 提供者应主动向孕妇推荐流感、Tdap、COVID-19和RSV疫苗,以提升接种覆盖率。
  • 针对疫苗犹豫的孕妇,提供者应开展信息性对话,利用其信任信息来源的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess end-of-season coverage with influenza, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), and COVID-19 vaccines among pregnant women, and respiratory syncytial virus (RSV) immunization among pregnant women and their infants, during the 2024-25 respiratory illness season. METHODS: Data from an Internet panel survey conducted during March 26-May 8, 2025, were analyzed. The study included 2738 currently and recently pregnant women; analysis of each immunization product was restricted to a subsample of participants eligible for the specific product (influenza: 1788; Tdap: 885; COVID-19: 2125; maternal RSV: 721; nirsevimab: 1416). Coverage was assessed for individual vaccines, along with demographic characteristics, provider recommendation for immunization, and attitudes, including perceptions on safety and effectiveness of vaccines. Differences in vaccination coverage between groups were assessed using t-tests. RESULTS: Among eligible participants, 51.0% reported receiving influenza vaccine before or during pregnancy, 52.6% reported receiving Tdap vaccine during pregnancy, 32.3% reported receiving the 2024-25 COVID-19 vaccine before or during pregnancy, and 49.3% reported receiving an RSV vaccine during pregnancy. Among 1416 women with eligible infants, 62.2% reported their infant received nirsevimab; overall, 70.4% of infants were protected by maternal RSV vaccine, nirsevimab, or both. Vaccination coverage was higher among women with a provider recommendation compared to those without for influenza (65.6% vs. 12.2%), Tdap (69.5% vs. 2.9%), and COVID-19 (56.4% vs. 4.4%) vaccines. Prevalence of provider recommendation for Tdap vaccination was lower among non-Hispanic Black (66.4%) and Hispanic women (60.1%) compared with non-Hispanic White women (83.2%). Women reporting being very/somewhat hesitant about a given vaccine were less likely than non-hesitant women to have received that vaccine. CONCLUSION: Provider recommendation and vaccine hesitancy were associated with maternal vaccine uptake. Because providers have been found to be trusted information sources for patients, efforts supporting informative vaccine conversations between providers and pregnant women could help increase the proportion of pregnant women and infants protected against severe respiratory illnesses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Razzaghi H, Garacci E, Kahn KE, et al. Maternal and infant immunizations for respiratory diseases, United States, may 2025. Vaccine. 2026. PMID: 42284808. doi:10.1016/j.vaccine.2026.128823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。